Alogliptin edges forward in Europe as EMA accepts filing
This article was originally published in Scrip
Executive Summary
Takeda has confirmed that an EU marketing authorisation application (MAA) for its oral antidiabetic alogliptin has been formally accepted for review by the European Medicines Agency.